D. Steensma

发表

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Donna Neuberg, Steven M Kornblau, Johannes Köster, 2016, Cancer cell.

Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy

G. Abel, L. Traeger, J. Temel, 2019, Leukemia.

Guideline-based indicators for adult patients with myelodysplastic syndromes.

D. Schwappach, D. Steensma, P. Fenaux, 2020, Blood advances.

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.

D. Gilliland, R. Levine, D. Gilliland, 2006, Blood.

Somatic point mutations in RUNX1/CBFA2/AML1 are common in high‐risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia

D. Higgs, D. Steensma, R. Mesa, 2005, European journal of haematology.

Biomedical system dynamics to improve anemia control with darbepoetin alfa in long-term hemodialysis patients.

D. Steensma, E. Bergstralh, J. McCarthy, 2014, Mayo Clinic proceedings.

Clonal Hematopoiesis: Crossroads of Aging, Cardiovascular Disease, and Cancer: JACC Review Topic of the Week.

P. Libby, B. Ebert, R. Blankstein, 2019, Journal of the American College of Cardiology.

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

James Allison, Stephen Forman, Massimo Cristofanilli, 2015, Mayo Clinic proceedings.

Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms

D. Steensma, C. Brierley, 2016, Current Hematologic Malignancy Reports.

Mutations in the chromatin‐associated protein ATRX

I. Krantz, D. Goudie, D. Steensma, 2008, Human mutation.

Acquired alpha-thalassemia in association with myelodysplastic syndrome and other hematologic malignancies.

D. Higgs, D. Steensma, R. Gibbons, 2005, Blood.

D. Higgs, D. Steensma, C. Fisher, 2002 .

Candidate gene mutation analysis in idiopathic acquired sideroblastic anemia (refractory anemia with ringed sideroblasts).

D. Steensma, T. Lasho, Kathleen A. Hecksel, 2007, Leukemia research.

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions

B. Ebert, A. Ganser, T. Haferlach, 2017, Oncotarget.

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.

A. Letai, S. Sallan, M. Harris, 2015, Cancer cell.

New challenges in evaluating anemia in older persons in the era of molecular testing.

D. Steensma, 2016, Hematology. American Society of Hematology. Education Program.

Anemia was independently associated with mortality in very old persons

D. Steensma, 2009, Annals of Internal Medicine.

Clinical Implications of Clonal Hematopoiesis

D. Steensma, 2018, Mayo Clinic proceedings.

Erythropoiesis stimulating agents

D. Steensma, 2007, BMJ : British Medical Journal.

The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.

D. Steensma, M. Wadleigh, R. Mesa, 2005, British journal of haematology.

The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates

D. Steensma, M. Wadleigh, R. Mesa, 2005 .

Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis

J. Barnard, G. Garcia-Manero, D. Steensma, 2018, Clinical Lymphoma, Myeloma & Leukemia.

An RNA bestiary in splicing-mutant MDS.

D. Steensma, 2018, Blood.

looking backward but moving forward – ash annual meeting 2011

D. Steensma, AsH NEWs, 2012 .

Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes.

D. Neuberg, B. Ebert, R. Bejar, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oncologists’ Reluctance to Use the Terms Hope and Cure: A Bibliometric Analysis of Articles From Two High-Impact Oncology Journals

C. Loprinzi, B. Corn, J. Bian, 2020, JNCI cancer spectrum.

Exacerbation of asthma by Florida "red tide" during an ocean sailing trip.

D. Steensma, 2007, Mayo Clinic proceedings.

Hematopoietic growth factors in myelodysplastic syndromes.

D. Steensma, 2011, Seminars in oncology.

New ASH/ASCO guidelines on the use of erythropoiesis-stimulating agents: a chorale amid cacophony.

D. Steensma, 2007, The journal of supportive oncology.

Special considerations in the management of patients with myelodysplastic myndrome / myeloproliferative neoplasm overlap syndromes during the SARS‐CoV‐2 pandemic

E. Solary, D. Steensma, A. Tefferi, 2020, American journal of hematology.

Erythropoietin use in cancer patients: a matter of life and death?

C. Loprinzi, D. Steensma, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

80-year-old woman with dizziness.

E. Matteson, D. Steensma, 1997, Mayo Clinic proceedings.

Patients with haematological malignancies should not have to choose between transfusions and hospice care.

O. Odejide, D. Steensma, Oreofe O. Odejide, 2020, The Lancet. Haematology.

Serum hepcidin levels predict response to intravenous iron and darbepoetin in chemotherapy-associated anemia.

J. Sloan, C. Loprinzi, D. Steensma, 2015, Blood.

Management of anemia in patients with cancer

D. Steensma, 2004, Current oncology reports.

Blood and Marrow Transplant Clinical Trials Network Study 1102 heralds a new era in hematopoietic cell transplantation in high‐risk myelodysplastic syndromes: Challenges and opportunities in implementation

D. Steensma, Bryce Waldman, A. Brunner, 2021, Cancer.

Hematopoietic Cell Transplantation for Myelodysplastic Syndromes.

D. Steensma, V. Bhatt, 2016, Journal of oncology practice.

HematopoieticCellTransplantation for Myelodysplastic Syndromes

D. Steensma, V. Bhatt, 2016 .

Tuning the rigging before sailing off into the stormy sea of stem cell transplants for patients with myelodysplastic syndromes.

D. Steensma, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?

D. Steensma, 2012, Best practice & research. Clinical haematology.

Assessment of ATRX expression in patients with myelodysplastic syndromes treated with decitabine.

D. Steensma, W. Hogan, M. Litzow, 2009, Leukemia research.

The spectrum of molecular aberrations in myelodysplastic syndromes: in the shadow of acute myeloid leukemia.

D. Steensma, 2007, Haematologica.

Targeting Aberrant Splicing in Myelodysplastic Syndromes: Biologic Rationale and Clinical Opportunity.

D. Steensma, A. Brunner, 2020, Hematology/oncology clinics of North America.

Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions

D. Neuberg, D. Kufe, D. DeAngelo, 2016, Science Translational Medicine.

Myelodysplastic syndromes current treatment algorithm 2018

D. Steensma, 2018, Blood Cancer Journal.

syndrome in both "atypical" myeloproliferative disorders and the myelodysplastic The JAK2 V617F activating tyrosine kinase mutation is an infrequent event

D. Steensma, H. Powell, A. Tefferi, 2013 .

myelodysplastic syndromes event in both ''atypical'' myeloproliferative disorders and The JAK2 V617F activating tyrosine kinase mutation is an infrequent

R. Levine, D. Gilliland, D. Steensma, 2013 .

55 patients with myeloproliferative disorders in EP300 and MYB More on Myb in myelofibrosis: molecular analyses of

W. Alexander, D. Hilton, J. Szer, 2011 .

More on Myb in myelofibrosis: molecular analyses of MYB and EP300 in 55 patients with myeloproliferative disorders.

W. Alexander, D. Hilton, J. Szer, 2006, Blood.

Elevated serum erythropoietin levels in patients with Budd‐Chiari syndrome secondary to polycythemia vera: clinical implications for the role of JAK2 mutation analysis

D. Steensma, P. Thurmes, 2006, European journal of haematology.

The JAK 2 V 617 F activating tyrosine kinase mutation is an infrequent event in both “ atypical ” myeloproliferative disorders and myelodysplastic syndromes

R. Levine, D. Gilliland, D. Steensma, 2005 .

Concomitant neutrophil JAK2V617F mutation screening and PRV‐1 expression analysis in myeloproliferative disorders and secondary polycythaemia

D. Gilliland, D. Gilliland, D. Steensma, 2005, British journal of haematology.

Historical expectations with DNA methyltransferase inhibitor monotherapy in MDS: when is combination therapy truly “promising”?

D. Steensma, A. Brunner, G. Fell, 2022, Blood advances.

What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)?

G. Garcia-Manero, D. Steensma, J. Lancet, 2021, Leukemia & lymphoma.

Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis

G. Garcia-Manero, J. Maciejewski, D. Steensma, 2021, Leukemia & lymphoma.

Fit Older Adults with Advanced Myelodysplastic Syndromes: Who is Most Likely to Benefit from Transplant?

G. Abel, D. DeAngelo, R. Soiffer, 2020, Leukemia.

Validation of International Working Group response criteria in higher‐risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium

J. Barnard, G. Garcia-Manero, D. Steensma, 2020, Cancer medicine.

Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities.

J. Barnard, H. Kantarjian, G. Garcia-Manero, 2020, Clinical lymphoma, myeloma & leukemia.

Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials.

G. Garcia-Manero, D. Steensma, P. Fenaux, 2019, Blood.

Rethinking clinical trial endpoints in myelodysplastic syndromes

D. Steensma, M. Sekeres, 2019, Leukemia.

Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence

B. Ebert, R. Bejar, J. Barnard, 2019, JCO precision oncology.

The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort.

Alexandra G. Smith, J. Maciejewski, D. Steensma, 2018, Blood advances.

Impact of lenalidomide use among non‐transfusion dependent patients with myelodysplastic syndromes

G. Abel, T. Graubert, D. Steensma, 2018, American journal of hematology.

Recent advances in the cellular and molecular understanding of myelodysplastic syndromes: implications for new therapeutic approaches.

D. Steensma, A. Brunner, 2018, Clinical advances in hematology & oncology : H&O.

Self‐reported sleep disturbance and survival in myelodysplastic syndromes

G. Abel, D. DeAngelo, D. Steensma, 2017, British journal of haematology.

Risk and timing of cardiovascular death among patients with myelodysplastic syndromes.

G. Abel, D. Neuberg, D. Steensma, 2017, Blood advances.

Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care

H. Kantarjian, G. Garcia-Manero, D. Steensma, 2017, Blood Cancer Journal.

The evolving role of genomic testing in assessing prognosis of patients with myelodysplastic syndromes.

D. Steensma, 2017, Best practice & research. Clinical haematology.

Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium

J. Barnard, G. Garcia-Manero, E. Jabbour, 2017, Leukemia.

Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC)*

J. Barnard, G. Garcia-Manero, D. Steensma, 2017, Leukemia & lymphoma.

Myelodysplastic syndromes: etiologies, evaluation, and therapy

D. Steensma, D. Henry, 2016 .

Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides

J. Barnard, H. Kantarjian, G. Garcia-Manero, 2016, Leukemia.

Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents.

J. Barnard, H. Kantarjian, G. Garcia-Manero, 2016, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts

P. Cin, K. Patel, D. Steensma, 2016, Modern Pathology.

Thrombopoiesis‐stimulating agents and myelodysplastic syndromes

D. Steensma, C. Brierley, 2015, British journal of haematology.

Comparing the Prognostic Value of Risk stratifying Models for Patients with Lower-Risk Myelodysplastic Syndromes: Is one model better?

J. Barnard, G. Garcia-Manero, J. Maciejewski, 2015, American journal of hematology.

Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies

D. Steensma, E. Padron, 2015, Current opinion in hematology.

Comparing the prognostic value of risk stratifying models for patients with lower‐risk myelodysplastic syndromes: Is one model better?

J. Barnard, G. Garcia-Manero, J. Maciejewski, 2015, American journal of hematology.

Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes

G. Garcia-Manero, D. Steensma, R. Stone, 2014, Cancer.

BONE MARROW FAILURE Recent developments in myelodysplastic syndromes

R. Bejar, D. Steensma, 2014 .

De novo acute myeloid leukemia with 20–29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study

D. Neuberg, V. Klepeis, A. Bagg, 2014, American journal of hematology.

Intensity of end‐of‐life care for patients with myelodysplastic syndromes: Findings from a large national database

G. Abel, O. Odejide, D. Steensma, 2016, Cancer.

When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?

D. Steensma, N. Gattermann, 2013, Best practice & research. Clinical haematology.

Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome.

D. Steensma, A. Raza, M. Baer, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Relevance of Iron Overload and the Appropriateness of Iron Chelation Therapy for Patients with Myelodysplastic Syndromes: A Dialogue and Debate

D. Steensma, 2011, Current hematologic malignancy reports.

High Serum Ferritin and Increased Risk of Complications of Allogeneic Stem Cell Transplantation

D. Steensma, 2011 .

Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis—increased serum ferritin or transfusion load does not

D. Steensma, R. Mesa, A. Tefferi, 2009, American journal of hematology.

Myelodysplasia paranoia: iron as the new radon.

D. Steensma, 2009, Leukemia research.

Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts

D. Steensma, A. Tefferi, Wenting Wu, 2008, American journal of hematology.

Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes.

D. Steensma, R. Stone, 2010, Hematology/oncology clinics of North America.

Decitabine treatment of patients with higher-risk myelodysplastic syndromes.

D. Steensma, 2009, Leukemia research.

Concomitant myelodysplastic syndrome and chronic myeloid leukaemia: treatment outcomes with imatinib mesylate

D. Steensma, R. Mesa, J. Hoyer, 2003, British journal of haematology.

Insurance Denial of Coverage for Patients Enrolled in Cancer Clinical Trials Is Still a Problem in the Affordable Care Act Era.

H. Kantarjian, D. Steensma, N. Jain, 2016, Journal of Oncology Practice.

Littoral Cell Angioma Associated with Portal Hypertension and Resected Colon Cancer

D. Steensma, W. Morice, 2001, Acta Haematologica.

How predictive is the finding of clonal hematopoiesis for the development of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)?

D. Steensma, 2021, Best practice & research. Clinical haematology.

The Clinical Challenge of Clonal Hematopoiesis, a Newly Recognized Cardiovascular Risk Factor.

P. Libby, B. Ebert, R. Levine, 2020, JAMA cardiology.

What To Tell Your Patient With Clonal Hematopoiesis And Why: Insights From Two Specialized Clinics.

D. Steensma, K. Bolton, 2020, Blood.

Does clonal hematopoiesis explain unexplained anemia?

D. Steensma, 2020, Blood.

Clonal Hematopoiesis at Crossroads of Aging, Cardiovascular Diseases, and Cancer: JACC Topic of the Week

P. Libby, B. Ebert, R. Blankstein, 2019 .

The Clinical Challenge of Idiopathic Cytopenias of Undetermined Significance (ICUS) and Clonal Cytopenias of Undetermined Significance (CCUS)

D. Steensma, 2019, Current Hematologic Malignancy Reports.

Clinical consequences of clonal hematopoiesis of indeterminate potential.

D. Steensma, 2018, Blood advances.

Clinical consequences of clonal hematopoiesis of indeterminate potential.

D. Steensma, 2018, Hematology. American Society of Hematology. Education Program.

Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms

S. Mccarroll, D. Neuberg, B. Ebert, 2018, Science Translational Medicine.

How I use molecular genetic tests to evaluate patients who have or may have myelodysplastic syndromes.

D. Steensma, 2018, Blood.

Comment on Kwok et al , page 2355 , and Cargo et al , page 2362 Cytopenias 1 mutations 2 dysplasia 5 what ?

D. Steensma, 2015 .

Cytopenias + mutations - dysplasia = what?

D. Steensma, 2015, Blood.

Myeloid Growth FactorsPractice Guidelines in Oncology

J. Armitage, G. Lyman, P. Westervelt, 2011 .

NCCN Myeloid Growth Factors Clinical Practice Guidelines in Oncology

J. Armitage, G. Lyman, P. Westervelt, 2011 .

Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromes

E. Zabor, D. Steensma, R. Stone, 2020, Cancer.

Submitting to autonomy.

D. Steensma, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A history of the kidney in plasma cell disorders.

R. Kyle, D. Steensma, 2007, Contributions to nephrology.

Congenital sideroblastic anemia associated with germline polymorphisms reducing expression of FECH

D. Steensma, J. C. Porcher, J. S. Caudill, 2008, Haematologica.

Young and Restless: Expansion of Donor-Origin Mutant HSCs after Transplantation.

D. Steensma, 2020, Cell stem cell.

A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death.

T. Therneau, R. Kyle, D. Steensma, 2001, Blood.

A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML)

D. Steensma, J. Lancet, M. Sekeres, 2016, Clinical Cancer Research.

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes

Jiqiang Yao, Q. Mo, H. Kantarjian, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study.

H. Kantarjian, G. Garcia-Manero, D. Steensma, 2019, The Lancet. Haematology.

SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype - A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM).

P. Campbell, M. Cazzola, D. Neuberg, 2020, Blood.

Short Telomere Length Predicts Non-Relapse Mortality after Stem Cell Transplantation for Myelodysplastic Syndrome.

D. Neuberg, Suneet Agarwal, D. Steensma, 2020, Blood.

Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey

R. Bejar, P. Greenberg, D. Steensma, 2020, Leukemia & lymphoma.

Systematic STAT3 sequencing in patients with unexplained cytopenias identifies unsuspected large granular lymphocytic leukemia.

J. Aster, E. Morgan, D. DeAngelo, 2017, Blood advances.

Cytopenias 1 mutations 2 dysplasia 5 what?

D. Steensma, 2015 .

MYELOID NEOPLASIA TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients

D. Neuberg, B. Ebert, P. Stojanov, 2014 .

Boulevard of broken dreams: drug approval for older adults with acute myeloid leukemia.

D. Steensma, M. Sekeres, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)

Scott E. Smith, G. Garcia-Manero, D. Steensma, 2012, Journal of Hematology & Oncology.

Low‐dose, single‐fraction, whole‐lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasia

D. Steensma, A. Tefferi, S. Stafford, 2002, British journal of haematology.

Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemia

L. Trippa, D. Steensma, S. Treon, 2021, Blood advances.

NPM1-mutant acute myeloid leukemia relapsing as acute lymphoblastic leukemia with clonal persistence of IDH1 mutation

Annette S. Kim, D. Steensma, M. Luskin, 2021, Leukemia & lymphoma.

In Response to Lymphohematopoietic Clones

B. Ebert, R. Bejar, D. Steensma, 2022, The Hematologist.

Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life.

G. Abel, D. Steensma, N. Young, 2014, Blood.

Deletion of the α-globin gene cluster as a cause of acquired α-thalassemia in myelodysplastic syndrome

D. Higgs, D. Steensma, V. Viprakasit, 2004 .

Steensma et al ATRX mutations in ATMDS 1 Acquired Somatic ATRX Mutations in Myelodysplastic Syndrome Associated with α Thalassemia (ATMDS) Convey a More Severe Hematological Phenotype than Germline ATRX Mutations

D. Higgs, D. Steensma, C. Fisher, 2003 .

Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data.

Dirk Rades, Guido Schwarzer, Jerome Seidenfeld, 2009, The Cochrane database of systematic reviews.

A phase III randomized trial of two different dosing schedules of erythropoietin (EPO) in patients with cancer-associated anemia: North Central Cancer Treatment Group (NCCTG) Study N02C2

P. Novotny, J. Sloan, C. Loprinzi, 2005 .

Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States

D. Zelterman, G. Garcia-Manero, D. Steensma, 2017, Transfusion.

Symptom control trials: a 20-year experience.

L. Minasian, P. Novotny, J. Sloan, 2007, The journal of supportive oncology.

Impact of cancer research bureaucracy on innovation, costs, and patient care.

H. Kantarjian, D. Steensma, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Platelet pathology in sex-linked GATA-1 dyserythropoietic macrothrombocytopenia II. Cytochemistry

D. Steensma, W. Nichols, J. White, 2007, Platelets.

The ABNL-MARRO 001 study: a phase 1–2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes

L. Pleyer, G. Ayers, E. Solary, 2022, BMC Cancer.

Putting it all together in CMML risk stratification.

D. Steensma, 2016, Blood.

Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome.

A. Dispenzieri, D. Steensma, A. Tefferi, 2003, Blood.

Hereditary red blood cell disorders in middle eastern patients.

D. Steensma, J. Hoyer, V. Fairbanks, 2001, Mayo Clinic proceedings.

A phase 2, randomized, double‐blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low‐ or intermediate‐1–risk myelodysplastic syndrome

G. Garcia-Manero, D. Steensma, R. Komrokji, 2014, American journal of hematology.

Myelodysplastic Syndromes.

D. Steensma, 2020, Hematology/oncology clinics of North America.

Uncoupling of CD71 shedding with mitochondrial clearance in reticulocytes in a subset of myelodysplastic syndromes

Mei X. Wu, D. Steensma, Qi Zhang, 2018, Leukemia.

Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia.

P. Novotny, J. Sloan, C. Loprinzi, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial.

Traci M. Blonquist, D. Neuberg, T. Graubert, 2019, The Lancet. Haematology.

Epoetin alfa and darbepoetin alfa go head to head.

C. Loprinzi, D. Steensma, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Becoming smarter about parenteral iron use in the oncology clinic

D. Steensma, 2012 .

Low efficacy and high mortality associated with clofarabine treatment of relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes.

D. DeAngelo, D. Steensma, R. Stone, 2015, Leukemia research.

Clonal cytogenetic abnormalities in bone marrow specimens without clear morphologic evidence of dysplasia: a form fruste of myelodysplasia?

D. Steensma, A. Tefferi, G. Dewald, 2003, Leukemia research.

Myelodysplastic syndrome associated with acquired beta thalassemia: “BTMDS”

D. Steensma, A. Brunner, 2016, American journal of hematology.

Does quality of life impact the decision to pursue stem cell transplantation for elderly patients with advanced MDS?

G. Abel, R. Soiffer, D. Steensma, 2016, Bone Marrow Transplantation.

Reply to M. Aapro et al

J. Sloan, C. Loprinzi, D. Steensma, 2011 .

Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment.

D. Steensma, M. Sekeres, 2009, Blood.

Incremental gains and a long road ahead in MDS.

D. Steensma, A. Tefferi, 2008, Oncology.

Predicting therapy-related myeloid neoplasms-and preventing them?

D. Steensma, 2017, The Lancet. Oncology.

Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States

D. Steensma, Xiaomei Ma, M. Sugrue, 2018, BMJ Open.

A call for action: Increasing enrollment of untreated patients with higher‐risk myelodysplastic syndromes in first‐line clinical trials

D. Steensma, S. Gore, M. Sekeres, 2017, Cancer.

Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: results from an internet-based survey.

J. Maciejewski, D. Steensma, R. Stone, 2011, The oncologist.

Out of this nettle, danger, we must pluck this flower, safety.

D. Steensma, 2009, Blood.

2364 1 7 S E P T E M B E R 2 0 0 9 I V O L U M E 1 1 4 , N U M B E R 1 2 Blood

M. Clinic, D. Steensma, 2009 .

Phase 1 Dose-Ranging Study of Oral Ezatiostat Hydrochloride (Telintra®, TLK199) in Combination with Lenalidomide (Revlimid®) in Patients with Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Scott E. Smith, G. Garcia-Manero, D. Steensma, 2011 .

Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

D. Neuberg, K. Ballen, D. DeAngelo, 2012, Leukemia research.

Outcomes of Patients with Myelodysplastic Syndromes (MDS) Who Achieve Stable Disease after Treatment with Hypomethylating Agents (HMA)

J. Barnard, H. Kantarjian, G. Garcia-Manero, 2014 .

Results of First in Human (FIH) Phase 1 Pharmacokinetic (PK) Guided Dose-Escalation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS)

G. Garcia-Manero, D. Steensma, P. Amrein, 2015 .

Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes

Tae Kon Kim, R. Bejar, O. Abdel-Wahab, 2022, Leukemia.

International working group for myelofibrosis research and treatment response assessment and long‐term follow‐up of 50 myelofibrosis patients treated with thalidomide‐prednisone based regimens

D. Steensma, R. Mesa, A. Tefferi, 2011, American journal of hematology.

A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes

T. Haferlach, G. Garcia-Manero, J. Maciejewski, 2018, Blood.

Genomic Biomarkers to Predict Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS)

B. Ebert, R. Bejar, J. Barnard, 2017 .

Validation of International Working Group (IWG) Response Criteria in Higher-Risk Myelodysplastic Syndromes (MDS): A Report on Behalf of the MDS Clinical Research Consortium (MDS CRC)

J. Barnard, G. Garcia-Manero, D. Steensma, 2015 .

Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial.

H. Kantarjian, G. Garcia-Manero, D. Steensma, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Successful Emulation of IV Decitabine Pharmacokinetics with an Oral Fixed-Dose Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine, in Subjects with Myelodysplastic Syndromes (MDS): Final Data of Phase 1 Study

H. Kantarjian, G. Garcia-Manero, D. Steensma, 2016 .

A Randomized Phase II Study of Low-Dose Decitabine Versus Azacitidine in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2016 .

Optimal Treatment Order of Lenalidomide and Hypomethylating Agents for Lower-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium

J. Barnard, G. Garcia-Manero, D. Steensma, 2016 .

Low-Dose Hypomethylating Agents (HMAs) Are Effective in Patients (Pts) with Low- or Intermediate-1-Risk Myelodysplastic Syndrome (MDS): A Report on Behalf of the MDS Clinical Research Consortium

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2015 .

High cancer drug prices in the United States: reasons and proposed solutions.

H. Kantarjian, D. Steensma, D. Light, 2014, Journal of oncology practice.

Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey*

Tae Kon Kim, D. Steensma, R. Stone, 2018, Leukemia & lymphoma.

Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents.

A. Stamatoullas, K. Götze, D. Steensma, 2020, Leukemia research.

Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia

D. Higgs, D. Steensma, R. Mesa, 2004 .

Platelet count is an IPSS‐independent risk factor predicting survival in refractory anaemia with ringed sideroblasts

D. Steensma, A. Tefferi, C. Hanson, 2008, British journal of haematology.

JAK2 V617F and ringed sideroblasts: not necessarily RARS-T.

D. Steensma, A. Tefferi, 2008, Blood.

MPL W515 and JAK2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated platelet count.

D. Steensma, A. Tefferi, T. Lasho, 2006, Haematologica.

Effects of the MEK inhibitor CI-1040 (PD 184352) on progenitor growth from normal and myelodysplastic marrow.

D. Steensma, R. Mesa, S. Kaufmann, 2003, Haematologica.

Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2V617F positive, del(5)(q13q33) myelodysplastic syndrome

D. Steensma, R. Mesa, A. Tefferi, 2006, Leukemia.

Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS

K. Do, H. Kantarjian, G. Garcia-Manero, 2022, NEJM Evidence.

Cardiac iron overload assessed by T2* magnetic resonance imaging and cardiac function in regularly transfused myelodysplastic syndrome patients

D. Steensma, E. Hellström-Lindberg, D. Bowen, 2014, British journal of haematology.

The role of iron chelation therapy for patients with myelodysplastic syndromes.

D. Steensma, 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

Iron Chelation with Deferasirox (Exjade®) Improves Iron Burden in Patients with Myelodysplastic Syndromes (MDS)

D. Steensma, A. Raza, M. Baer, 2008 .

Myelodysplastic Syndromes : Pathobiology and Clinical Management

D. Steensma, 2008 .

Erythropoiesis‐stimulating agents are effective in myelodysplastic syndromes, but are they safe?

D. Steensma, 2009, American journal of hematology.

Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndrome.

D. Steensma, A. Tefferi, M. Elliott, 2001, Leukemia research.

Novel therapies for myelodysplastic syndromes.

D. Steensma, 2010, Hematology/oncology clinics of North America.

Genomic landscape of Neutrophilic Leukemias of Ambiguous Diagnosis.

R. Collins, Emily A. Stevens, D. Bottomly, 2019, Blood.

Dysgranulopoiesis is an independent adverse prognostic factor in chronic myeloid disorders with an isolated interstitial deletion of chromosome 5q

D. Steensma, A. Tefferi, J. Hoyer, 2009, Leukemia.

Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study.

E. Vellenga, D. Steensma, P. Fenaux, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive

E. Vellenga, D. Steensma, P. Fenaux, 2018, Blood.

The Use of Immunosuppressive Therapy (IST) in Patients with the Myelodysplastic Syndromes (MDS): Clinical Outcomes and Their Predictors in a Large International Patient Cohort

L. Arenillas, D. Steensma, P. Fenaux, 2017 .

Undertreatment of Patients (Pts) with Myelodysplastic Syndromes (MDS): Analysis of a Large Electronic Medical Records (EMR) Database Cohort of US Pts with MDS

D. Steensma, Xiaomei Ma, M. Sugrue, 2016 .

Myelodysplastic Syndrome Patients Obtaining a Cytogenetic Response to Outpatient Decitabine Experience Improved Hematological Responses and Longer Survival: Additional Analyses From the ADOPT Trial.

D. Steensma, S. Goldberg, 2009 .

Outcomes for older adults with acute myeloid leukemia after an intensive care unit admission

G. Abel, J. Temel, D. DeAngelo, 2019, Cancer.

Two-Year Analysis of Efficacy and Safety of Deferasirox (Exjade®) Treatment in Myelodysplastic Syndrome Patients Enrolled in the US03 Study.

D. Steensma, A. Raza, M. Baer, 2009 .

Deferasirox (ICL670; Exjade®) Reduces Serum Ferritin (SF) and Labile Plasma Iron (LPI) in Patients with Myelodysplastic Syndromes (MDS).

D. Steensma, A. Raza, M. Baer, 2007 .

Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)

Jiqiang Yao, Q. Mo, H. Kantarjian, 2019, Blood.

An Open-Label, Phase 2, Dose-Finding Study of Sotatercept (ACE-011) in Patients with Low or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Chronic Myelomonocytic Leukemia (CMML) and Anemia Requiring Transfusion

A. Stamatoullas, G. Garcia-Manero, D. Steensma, 2014 .

O-024 Next-generation sequencing of 213 MDS patient samples identifies mutation profiles associated with response to hypomethylating agents and overall survival

K. Cibulskis, D. Neuberg, B. Ebert, 2013 .

The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis.

J. Sloan, H. Kantarjian, S. Verstovsek, 2009, Leukemia research.

Lenalidomide (CC-5013) Treatment for Anemia Associated with Myelofibrosis with Myeloid Metaplasia.

D. Steensma, R. Mesa, A. Tefferi, 2005 .

A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia

B. Ebert, K. Ballen, D. DeAngelo, 2018, American journal of hematology.

Independent Validation of the MD Anderson Cancer Center Risk Model for Myelodysplastic Syndromes (MDS), and Comparison to the International Prognostic Scoring System (IPSS) and the World Health Organization-Based Prognostic Scoring System (WPSS).

D. Steensma, C. Hanson, Sarah E. Hugo, 2009 .

Perceptions of Disease State, Treatment Expectations, and Prognosis Among Patients with Myelodysplastic Syndromes.

J. Maciejewski, D. Steensma, R. Stone, 2009 .

RAD51 and XRCC3 polymorphism frequency and risk of myelodysplastic syndromes

D. Steensma, L. Baumann Kreuziger, 2008, American journal of hematology.

Initial experience with L-leucine therapy in myelodysplastic syndromes with associated chromosome 5q deletion.

B. Ebert, D. Steensma, 2013, Blood.

Lenalidomide in AML: del(5q) or who?

D. Steensma, R. Stone, 2011, Blood.

X-linked macrocytic dyserythropoietic anemia in females with an ALAS2 mutation.

Jacob C. Ulirsch, R. Bejar, D. Steensma, 2015, The Journal of clinical investigation.

An extreme example of focal bone marrow involvement in acute myeloid leukemia

E. Morgan, D. Steensma, C. Brierley, 2013, American journal of hematology.

Reply to H. Kantarjian et al.

D. Steensma, M. Sekeres, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rearrangements and amplification of IER3 (IEX-1) represent a novel and recurrent molecular abnormality in myelodysplastic syndromes.

J. Keats, P. L. Bergsagel, Rajiv Kumar, 2009, Cancer research.

Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials

M. Zwahlen, M. Egger, M. Schumacher, 2009, The Lancet.

A randomized comparison of once weekly epoetin alfa to extended schedule epoetin or darbepoetin in chemotherapy‐associated anemia

P. Novotny, J. Sloan, D. Moore, 2015, American journal of hematology.

Abbie Lathrop, the "mouse woman of Granby": rodent fancier and accidental genetics pioneer.

R. Kyle, D. Steensma, M. Shampo, 2010, Mayo Clinic proceedings.

The kiss of death: a severe allergic reaction to a shellfish induced by a good-night kiss.

D. Steensma, 2003, Mayo Clinic proceedings.

Prospects and perils of retrospective risk assessment of erythropoiesis‐stimulating agents

D. Steensma, 2008, American journal of hematology.

Overcoming obstacles to hospice care: an ethical examination of inertia and inaction.

D. Steensma, C. Daugherty, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study.

D. Steensma, R. Mesa, A. Tefferi, 2002, Blood.

Doctor-Patient Communication and Perception of Treatment Discontinuation in Myelodysplastic Syndromes (MDS) Diverge at the Time of Disease Progression

G. Garcia-Manero, J. Maciejewski, D. Steensma, 2014 .

Phase 1b/2 Combination Study of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Jiqiang Yao, G. Garcia-Manero, D. Steensma, 2018, Blood.

Monocytic skin nodules in chronic myelomonocytic leukemia: Clinical response to decitabine therapy

D. Steensma, B. Friday, 2007, Leukemia & lymphoma.

Flow cytometric methods for detection and quantification of apoptosis.

D. Steensma, T. Witzig, M. Timm, 2003, Methods in molecular medicine.

S837 TREATMENT WITH IMETELSTAT PROVIDES DURABLE TRANSFUSION INDEPENDENCE (TI) IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER RISK MDS (LR-MDS) RELAPSED/REFRACTORY (R/R) TO ERYTHROPOIESIS STIMULATING AGENTS (ESAS)

E. Vellenga, D. Steensma, P. Fenaux, 2019, HemaSphere.

Myelodysplasia, megakaryocytes, and methylation.

D. Steensma, 2004, Leukemia research.

Myeloproliferative Disorders and the Chronic Leukemias: Symptom Burden and Impact in Quality of Life

T. Shanafelt, D. Steensma, R. Mesa, 2010 .

Fertility preservation in women with marrow failure syndromes prior to allogeneic stem cell transplantation

D. Steensma, E. Ginsburg, P. Brady, 2018, American journal of hematology.

Long-Term Outcome of Myelodysplastic Syndromes (MDS) Patients Treated with Erythropoiesis Stimulating Agents (ESAs)

J. Barnard, G. Garcia-Manero, J. Maciejewski, 2015 .

Development of a disease-specific measure of quality of life in myelodysplastic syndromes (MDS): The “QUALMS-1”.

G. Abel, Yolanda Martins, D. Steensma, 2012 .

Isolated trisomy 15: a clonal chromosome abnormality in bone marrow with doubtful hematologic significance.

D. Steensma, J. Hoyer, P. Nguyen, 2008, American journal of clinical pathology.

The Patient Protection and Affordable Care Act: Is it good or bad for oncology?

H. Kantarjian, D. Steensma, D. Light, 2014, Cancer.

Niche-based screening identifies small-molecule inhibitors of leukemia stem cells.

Fatima Al-Shahrour, Anne E Carpenter, Benito Munoz, 2013, Nature chemical biology.

14 A PHASE 2, DOSE-FINDING STUDY OF SOTATERCEPT (ACE-011) IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS) OR NON-PROLIFERATIVE CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) AND ANEMIA REQUIRING TRANSFUSION

A. Stamatoullas, G. Garcia-Manero, D. Steensma, 2015 .

Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-Risk Myelodysplastic Syndrome (HR-MDS) after Failure of Hypomethylating Agents (HMAs)

R. Collins, P. Greenberg, G. Gaidano, 2014 .

"Congo" red: out of Africa?

D. Steensma, 2001, Archives of pathology & laboratory medicine.

Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia.

D. Steensma, R. Mesa, S. Kaufmann, 2002, Blood.

An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)

J. Esteve, M. Cazzola, R. Schlenk, 2015 .

320 RISK STRATIFICATION OF THERAPY-RELATED MYELODYSPLASTIC SYNDROMES (T-MDS): A REPORT ON BEHALF OF THE MDS CLINICAL RESEARCH CONSORTIUM

G. Garcia-Manero, E. Jabbour, D. Steensma, 2015 .

Pure red cell aplasia associated with thymoma: clinical insights from a 50‐year single‐institution experience *

D. Steensma, C. Thompson, 2006, British journal of haematology.

Clonal Hematopoiesis after Induction Chemotherapy for Acute Myeloid Leukemia.

B. Ebert, D. Steensma, 2018, The New England journal of medicine.

Current Diagnosis Patterns for Acute Myeloid Leukemia (AML) in Clinical Practice Compared with World Health Organization (WHO) 2008 Recommendations: Outcomes from the CONNECT® Myelodysplastic Syndromes (MDS) and AML Disease Registry

R. Bejar, D. Revicki, G. Garcia-Manero, 2016 .

Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.

D. Neuberg, B. Ebert, N. Lindeman, 2015, Blood.

Outcome of patients with low‐risk and intermediate‐1‐risk myelodysplastic syndrome after hypomethylating agent failure: A report on behalf of the MDS Clinical Research Consortium

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2015, Cancer.

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups

P. Campbell, M. Cazzola, D. Neuberg, 2019, Leukemia.

unselected anemic patients with myelodysplastic syndrome Antithymocyte globulin has limited efficacy and substantial toxicity in

A. Dispenzieri, D. Steensma, S. Moore, 2011 .

Autoimmune hemolytic anemia in a patient with autosomal dominant chronic mucocutaneous candidiasis.

D. Steensma, A. Tefferi, C. Weiler, 2000, Mayo Clinic proceedings.

Platelet pathology in sex-linked GATA-1 dyserythropoietic macrothrombocytopenia I ultrastructure

D. Steensma, W. Nichols, J. White, 2007, Platelets.

Is refractory anaemia with ring sideroblasts and thrombocytosis (RARS‐T) a necessary or useful diagnostic category?

D. Steensma, D. Wardrop, 2009, British journal of haematology.

Congenital Erythropoietic Porphyria, β-Thalassemia Intermedia and Thrombocytopenia Due to a GATA1 Mutation.

D. Steensma, J. Phillips, G. Spangrude, 2005 .

The Blood of the Lamb.

D. Steensma, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Historical perspectives on myelodysplastic syndromes.

D. Steensma, 2012, Leukemia research.

Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.

B. Ebert, R. Bejar, D. Steensma, 2015, Blood.

Graphical representation of clinical outcomes for patients with myelodysplastic syndromes

D. Steensma, 2016, Leukemia & lymphoma.

Clonal Hematopoiesis and Measurable Residual Disease Assessment in Acute Myeloid Leukemia.

B. Ebert, T. Graubert, D. Steensma, 2020, Blood.

Anemia in the Young and Old

D. Steensma, 2019, Springer International Publishing.

The Well-Being and Personal Wellness Promotion Strategies of Medical Oncologists in the North Central Cancer Treatment Group

J. Sloan, T. Shanafelt, P. Novotny, 2005, Oncology.

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts

P. Vyas, A. Goldberg, A. Verma, 2020, The Lancet Haematology.

Why does my patient have lymphadenopathy or splenomegaly?

D. Steensma, G. Motyckova, Gabriela Motyckova, 2012, Hematology/oncology clinics of North America.

The In-Training Examination in Internal Medicine.

D. Steensma, 2003, Annals of internal medicine.

Good riddance to the term "refractory anemia" in myelodysplastic syndromes.

D. Steensma, 2016, Leukemia research.

The myelodysplastic syndromes: diagnosis and treatment.

J. Bennett, D. Steensma, 2006, Mayo Clinic proceedings.

JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained

D. Steensma, H. Powell, J. Karp, 2006, Leukemia.

first trans-acting mutation causative for a human porphyria Congenital erythropoietic porphyria due to a mutation in GATA1: the

D. Steensma, J. Phillips, M. Pulsipher, 2013 .

SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS

P. Campbell, M. Cazzola, D. Neuberg, 2020, Blood.

Hydroxyurea-associated platelet count oscillations in polycythemia vera: a report of four new cases and a review.

D. Steensma, A. Tefferi, C. Harrison, 2001 .

Congenital erythropoietic porphyria due to a mutation in GATA1: the first trans-acting mutation causative for a human porphyria.

D. Steensma, J. Phillips, M. Pulsipher, 2007, Blood.

Acquired alpha-thalassemia in association with myelodysplastic syndrome and other hematologic malignancies.

D. Higgs, D. Steensma, R. Gibbons, 2005, Blood.

AGenome-WideAberrantRNASplicing inPatientswithAcute MyeloidLeukemia IdentifiesNovelPotentialDiseaseMarkers and Therapeutic Targets

P. Pilarski, John Quackenbush, B. Haibe-Kains, 2014 .

A Genome-Wide Aberrant RNA Splicing in Patients with Acute Myeloid Leukemia Identifies Novel Potential Disease Markers and Therapeutic Targets

P. Pilarski, John Quackenbush, B. Haibe-Kains, 2013, Clinical Cancer Research.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Donna Neuberg, Steven M Kornblau, Johannes Köster, 2016, Cancer cell.

The myelodysplastic syndrome(s): a perspective and review highlighting current controversies.

D. Steensma, A. Tefferi, 2003, Leukemia research.

Genomic alterations in patients with somatic loss of the Y chromosome as the sole cytogenetic finding in bone marrow cells

P. D. Dal Cin, D. Steensma, O. Weinberg, 2020, Haematologica.

The leukemias: a half-century of discovery.

D. Steensma, E. Freireich, P. Wiernik, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant

G. Getz, C. Stewart, D. Neuberg, 2020, Nature Communications.

The DNA Damage Response, DNA Repair, and AML

D. Steensma, 2007 .

Molecular Genetics of Myelodysplastic Syndromes

R. Bejar, D. Steensma, 2012 .

JAK2 V617F in myeloid disorders: What do we know now, and where are we headed?

D. Steensma, M. Nelson, 2006, Leukemia & lymphoma.

Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity.

D. Steensma, A. List, 2005, Mayo Clinic proceedings.

Loss of 5q in myeloid malignancies - A gain in understanding of biological and clinical consequences.

D. Steensma, J. Mascarenhas, S. Venugopal, 2020, Blood reviews.

Myelodysplastic Syndrome and Pregnancy: The Mayo Clinic Experience

D. Steensma, A. Tefferi, 2001, Leukemia & lymphoma.

Implications of Clonal Hematopoiesis for Precision Oncology.

D. Steensma, P. Miller, 2020, JCO precision oncology.

Clonal Hematopoiesis as a Model for Premalignant Changes During Aging.

B. Ebert, D. Steensma, 2019, Experimental hematology.

Myelodysplastic Syndromes: Diagnosis and Treatment.

David P Steensma, D. Steensma, 2015, Mayo Clinic proceedings.

New Insights from Studies of Clonal Hematopoiesis

D. Steensma, C. Gibson, 2018, Clinical Cancer Research.

High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML.

T. Graubert, D. DeAngelo, R. Soiffer, 2018, Blood.

Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms.

W. Wong, A. Bagg, R. Ptashkin, 2019, Blood advances.

Recent developments in myelodysplastic syndromes.

R. Bejar, D. Steensma, 2014, Blood.

Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms

I. Flinn, H. Deeg, F. Thol, 2021, Leukemia.

Stress-induced hematopoietic failure in the absence of immediate early response gene X-1 (IEX-1, IER3)

Charles P. Lin, Mei X. Wu, D. Steensma, 2014, Haematologica.

The bone-marrow niche in MDS and MGUS: implications for AML and MM

D. Steensma, I. Ghobrial, A. Detappe, 2018, Nature Reviews Clinical Oncology.

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.

David P Steensma, Ayalew Tefferi, D. Gilliland, 2005, Blood.

Oral cedazuridine/decitabine: a phase 2, pharmacokinetic/pharmacodynamic, randomized, crossover study in MDS and CMML.

H. Kantarjian, G. Garcia-Manero, R. Wells, 2020, Blood.

Blockade of IL-22 signaling reverses erythroid dysfunction in stress-induced anemias

A. Regev, S. Carr, S. Waikar, 2021, Nature Immunology.

Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant

G. Getz, C. Stewart, D. Neuberg, 2020, Nature Communications.

TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.

D. Neuberg, B. Ebert, P. Stojanov, 2014, Blood.

Vascular and Metabolic Implications of Novel Targeted Cancer Therapies: Focus on Kinase Inhibitors.

D. Steensma, J. Moslehi, K. Croce, 2015, Journal of the American College of Cardiology.

Cytogenetic and Molecular Genetic Aspects of Essential Thrombocythemia

D. Steensma, A. Tefferi, 2002, Acta Haematologica.

On the TRAIL of a new therapy for leukemia

D. Steensma, S. Kaufmann, 2005, Leukemia.

Bone marrow niches in haematological malignancies

J. Gribben, D. Steensma, I. Ghobrial, 2020, Nature Reviews Cancer.

Aberrant pre-mRNA splicing of a highly conserved cell cycle regulator, CDC25C, in myelodysplastic syndromes

D. Steensma, J. C. Porcher, J. S. Caudill, 2008, Leukemia & lymphoma.

Sister (Mary) Joseph's Nodule

D. Steensma, 2000, Annals of Internal Medicine.

Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer.

David P Steensma, P. Novotny, J. Sloan, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk-based management of myelodysplastic syndrome.

D. Steensma, A. Tefferi, 2007, Oncology.

Detection of the KITD816V mutation in myelodysplastic and/or myeloproliferative neoplasms and acute myeloid leukemia with myelodysplasia-related changes predicts concurrent systemic mastocytosis

Annette S. Kim, G. Pinkus, J. Aster, 2020, Modern Pathology.

Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation.

D. Neuberg, B. Ebert, P. Stojanov, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions

G. Garcia-Manero, D. Steensma, M. Sekeres, 2018, Cancer.

Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia

D. Steensma, R. Mesa, D. Loegering, 2006, Leukemia.

Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia

D. Neuberg, J. Kolitz, K. Stevenson, 2016, Cancer.

ASH 2010 meeting report—Top 10 clinically‐oriented abstracts in myelodysplastic syndromes (MDS)

D. Steensma, 2011 .

Marrow failure syndromes

J. Maciejewski, D. Steensma, 2010 .

Are myelodysplastic syndromes "cancer"? Unexpected adverse consequences of linguistic ambiguity.

David P Steensma, D. Steensma, 2006, Leukemia research.

The molecular pathogenesis of myelodysplastic syndromes

M. Davids, D. Steensma, 2010, Cancer biology & therapy.

A novel 5' ATRX mutation with splicing consequences in acquired alpha thalassemia-myelodysplastic syndrome.

D. Steensma, J. Hoyer, M. Nelson, 2005, Haematologica.

The phenotypic spectrum of germline YARS2 variants: from isolated sideroblastic anemia to mitochondrial myopathy, lactic acidosis and sideroblastic anemia 2

L. Arenillas, M. Fleming, D. Swinkels, 2018, Haematologica.

The phenotypic spectrum of germline YARS2 variants: from isolated sideroblastic anemia to mitochondrial myopathy, lactic acidosis and sideroblastic anemia 2

L. Arenillas, M. Fleming, D. Swinkels, 2018, Haematologica.

Dysplasia Has A Differential Diagnosis: Distinguishing Genuine Myelodysplastic Syndromes (MDS) From Mimics, Imitators, Copycats and Impostors

D. Steensma, 2012, Current Hematologic Malignancy Reports.

SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value.

G. Garcia-Manero, D. Steensma, A. Tefferi, 2012, Blood.

the treatment of myelofibrosis with myeloid metaplasia A phase 2 trial of combination low-dose thalidomide and prednisone for

D. Steensma, R. Mesa, A. Tefferi, 2012 .

History of multiple myeloma.

R. Kyle, D. Steensma, 2011, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

A Multicenter Phase II Study Using a Dose Intensified Pegylated-Asparaginase Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia: A DFCI ALL Consortium Trial

D. Neuberg, S. Sallan, L. Silverman, 2015 .

Staunching the rising costs of haematological health care.

D. Steensma, G. Ruiz-Argüelles, 2016, The Lancet. Haematology.

The chronic myeloproliferative disorders: an historical perspective.

D. Steensma, 2003, Current hematology reports.

Outdated dogma? Busulfan, seizure prophylaxis, and stem cell allografting

D. Steensma, G. Ruiz-Argüelles, D. Gómez-Almaguer, 2012, American journal of hematology.

Splenic histopathological patterns in chronic myelomonocytic leukemia with clinical correlations: reinforcement of the heterogeneity of the syndrome.

D. Steensma, A. Tefferi, Chin‐Yang Li, 2003, Leukemia research.

Oddballs: acute leukemias of mixed phenotype and ambiguous origin.

D. Steensma, 2011, Hematology/oncology clinics of North America.

Sir Brian Gerald Barratt-Boyes-pioneer cardiac surgeon.

R. Kyle, D. Steensma, M. Shampo, 2012, Mayo Clinic proceedings.

Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS).

Tae Kon Kim, R. Bejar, O. Abdel-Wahab, 2023, Blood reviews.

A novel large deletion and three polymorphisms in the FECH gene associated with erythropoietic protoporphyria

D. Steensma, M. Cappellini, E. Di Pierro, 2009, Clinical chemistry and laboratory medicine.

Host immunity affects survival in myelodysplastic syndromes: Independent prognostic value of the absolute lymphocyte count

D. Steensma, A. Tefferi, S. Markovic, 2010, American journal of hematology.

Myeloid growth factors.

J. Armitage, M. Dwyer, H. Rugo, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

New Strategies in Myelodysplastic Syndromes: Application of Molecular Diagnostics to Clinical Practice

B. Ebert, Z. Tothova, D. Steensma, 2013, Clinical Cancer Research.

Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.

A. Stamatoullas, K. Götze, P. Cony-Makhoul, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure

J. Barnard, H. Kantarjian, G. Garcia-Manero, 2016, Haematologica.

What Is the Optimal Time to Initiate Hypomethylating Agents (HMA) in Higher Risk Myelodysplastic Syndromes (MDS)?

G. Garcia-Manero, D. Steensma, J. Lancet, 2018, Blood.

Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents

D. Steensma, Daniel A Roberts, Daniel A. Roberts, 2015, Current Hematologic Malignancy Reports.

Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia

D. Steensma, A. Zeidan, R. Rampal, 2016, Annals of Hematology.

Preliminary Results of a Phase II Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults with Myelodysplastic Syndrome (MDS).

H. Kantarjian, D. Steensma, M. Baer, 2007 .

Down syndrome in Down House: trisomy 21, GATA1 mutations, and Charles Darwin.

D. Steensma, 2005, Blood.

Absence of mutations in the key megakaryocyte transcriptional regulator FOG‐1 in patients with idiopathic myelofibrosis

P. Vyas, D. Steensma, J. Reilly, 2004, British journal of haematology.

Influence of patient and provider characteristics on quality of care for the myelodysplastic syndromes

H. Uno, D. Steensma, A. Cronin, 2016, British journal of haematology.

Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults.

G. Abel, D. DeAngelo, I. Galinsky, 2015, Journal of geriatric oncology.

Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes.

G. Abel, D. DeAngelo, D. Steensma, 2013, Leukemia research.

DC/Aml Fusion Cell Vaccination Administered to AML Patients Who Achieve a Complete Remission Potently Expands Leukemia Reactive T Cells and Is Associated with Durable Remissions

D. Neuberg, D. Kufe, D. DeAngelo, 2015 .

Clinical Trial Evaluating DC/AML Fusion Cell Vaccination In AML Patients

D. Neuberg, D. Kufe, D. DeAngelo, 2013 .

Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey.

J. Sloan, P. Novotny, J. Bennett, 2008, Leukemia research.

Is anemia of cancer different from chemotherapy-induced anemia?

D. Steensma, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

James Till and Ernest McCulloch: Hematopoietic Stem Cell Discoverers.

R. Kyle, D. Steensma, 2021, Mayo Clinic proceedings.

Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2017, Blood.

Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)

A. Stamatoullas, B. Quesnel, Q. Mo, 2021, Blood.

Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes

T. Haferlach, G. Garcia-Manero, J. Maciejewski, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases.

D. Steensma, A. Tefferi, G. Dewald, 2008, Leukemia research.

JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.

D. Steensma, 2006, The Journal of molecular diagnostics : JMD.

Chromosome 5q deletion: specific diagnoses and cytogenetic details among 358 consecutive cases from a single institution.

D. Steensma, A. Tefferi, G. Dewald, 2008, Leukemia research.

Hydroxyurea-associated Platelet Count Oscillations in Polycythemia Vera: A Report of Four New Cases and a Review

D. Steensma, A. Tefferi, C. Harrison, 2001, Leukemia & lymphoma.

A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.

D. Steensma, R. Mesa, S. Kaufmann, 2003, Blood.

Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.

R. Collins, P. Greenberg, G. Gaidano, 2016, The Lancet. Oncology.

Bone marrow niches in haematological malignancies

J. Gribben, D. Steensma, I. Ghobrial, 2020, Nature Reviews Cancer.

Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study

R. Bejar, G. Garcia-Manero, J. Maciejewski, 2016, BMC Cancer.

Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study

R. Bejar, G. Garcia-Manero, J. Maciejewski, 2016, BMC Cancer.

Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms

R. Bejar, C. Hourigan, D. Steensma, 2022, Leukemia.

NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML.

P. Pilarski, John Quackenbush, Benjamin Haibe-Kains, 2014, Blood.

A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival.

G. Garcia-Manero, Jacqueline S. Garcia, D. Steensma, 2021, Leukemia research.

J. Esteve, M. Cazzola, R. Schlenk, 2020, Leukemia.

Allogeneic stem cell transplantation in myelodysplastic syndromes: does pretransplant clonal burden matter?

D. Steensma, C. Brierley, 2016, Current opinion in hematology.

J. Barnard, D. Steensma, M. Sekeres, 2017, Leukemia.

Anemia in the elderly: how should we define it, when does it matter, and what can be done?

D. Steensma, A. Tefferi, 2007, Mayo Clinic proceedings.

Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia‐negative acute lymphoblastic leukemia in first remission

D. Neuberg, K. Ballen, R. Soiffer, 2016, American journal of hematology.

Should the ASCO/ASH Guidelines for the use of intravenous iron in cancer- and chemotherapy-induced anemia be updated?

D. Steensma, A. Gafter-Gvili, M. Auerbach, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

ASH 2009 meeting report—Top 10 clinically oriented abstracts in myelodysplastic syndromes

D. Steensma, 2010 .

Myelodysplasia with fibrosis: a distinct entity?

D. Steensma, A. Tefferi, C. Hanson, 2001, Leukemia research.

Lack of efficacy of pyridoxine (vitamin B6) treatment in acquired idiopathic sideroblastic anaemia, including refractory anaemia with ring sideroblasts

D. Steensma, A. Wolanskyj, L. Baumann Kreuziger, 2011, European journal of haematology.

Life‐threatening desquamating rash and hyperammonemia following administration of eculizumab for paroxysmal nocturnal hemoglobinuria

D. Steensma, L. Letendre, B. Knoll, 2008, American journal of hematology.

Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.

A. Stamatoullas, G. Garcia-Manero, G. Borthakur, 2018, The Lancet. Haematology.

Isolated splenic sinus histiocytosis (Rosai-Dorfman disease) in association with myelodysplastic syndrome.

D. Steensma, Paul J. Kurtin, S. Knox, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multiple Myeloma - a New Era of Treatment Strategies

G. Tonon, S. Lonial, D. Ribatti, 2012 .

Cancer research in the United States: A critical review of current status and proposal for alternative models

Razelle Kurzrock, David P Steensma, R. Kurzrock, 2018, Cancer.

Walter Clement Noel—first patient described with sickle cell disease.

R. Kyle, D. Steensma, M. Shampo, 2010, Mayo Clinic proceedings.

The art and science of prognosis in patients with advanced cancer.

C. Loprinzi, D. Steensma, 2000, European journal of cancer.

Hans Geiger-German physicist and the Geiger counter.

Marc A Shampo, Robert A Kyle, David P Steensma, 2011, Mayo Clinic proceedings.

Advanced heart failure and nocturnal hypoxaemia due to central sleep apnoea are associated with increased serum erythropoietin

V. Somers, D. Steensma, C. Scott, 2010, European journal of heart failure.

Potentially avoidable hospital admissions in older patients with acute myeloid leukaemia in the USA: a retrospective analysis.

G. Abel, L. Traeger, J. Temel, 2016, The Lancet. Haematology.

Compassionate honesty.

C. Loprinzi, D. Steensma, T. Moynihan, 2010, Journal of palliative medicine.

Truth Telling and Palliative Care

D. Steensma, L. Schapira, 2013 .

Fifty years of Tart cells.

D. Steensma, 1999, Mayo Clinic proceedings.

Treatment of Persons with Multiple Myeloma in Underprivileged Circumstances: Real-World Data from a Single Institution

D. Steensma, G. Ruiz-Argüelles, G. Ruiz-Delgado, 2020, Acta Haematologica.

Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS)

G. Abel, Yolanda Martins, D. Steensma, 2016, Haematologica.

Patient‐Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia

G. Abel, L. Traeger, J. Temel, 2018, The Oncologist.

Adolf Butenandt--Nobel Prize for chemistry.

R. Kyle, D. Steensma, M. Shampo, 2012, Mayo Clinic proceedings.

The Hippocratic Oath, the US Health Care System, and the Affordable Care Act in 2015.

H. Kantarjian, D. Steensma, A. Tefferi, 2015, The American journal of medicine.

Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect® MDS/AML Disease Registry

R. Bejar, D. Revicki, G. Garcia-Manero, 2020, EJHaem.

Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome.

D. Neuberg, Suneet Agarwal, D. Steensma, 2020, Blood.

The changing classification of myelodysplastic syndromes: what's in a name?

D. Steensma, 2009, Hematology. American Society of Hematology. Education Program.

Real‐world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower‐risk myelodysplastic syndromes

D. Revicki, G. Garcia-Manero, J. Maciejewski, 2020, International journal of laboratory hematology.

The beginning of the end of the beginning in cancer genomics.

D. Steensma, 2013, The New England journal of medicine.

Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia

Q. Mo, D. Steensma, J. Lancet, 2021, Clinical Cancer Research.

Contract research organizations in oncology clinical research: Challenges and opportunities

David P Steensma, H. Kantarjian, D. Steensma, 2016, Cancer.

Loss-Of-Function Mutations In The Splicing Factor ZRSR2 Are Common In Blastic Plasmacytoid Dendritic Cell Neoplasm and Have Male Predominance

F. Jardin, N. Harris, D. Neuberg, 2013 .

Myelodysplastic syndromes (MDS) occurring in Agent Orange exposed individuals carry a mutational spectrum similar to that of de novo MDS

B. Ebert, D. Steensma, A. Sperling, 2019, Leukemia & lymphoma.

Albin Lambotte: Pioneer of Osteosynthesis (Bone Fixation).

R. Kyle, D. Steensma, A. Afshar, 2021, Mayo Clinic proceedings.

Abstract CT068: Phase Ib/II combination study of APR-246 and azacitidine (AZA) in patients withTP53mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)

A. Graber, G. Garcia-Manero, D. Steensma, 2018, Clinical Trials.

Safety and Efficacy of Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant Naïve Settings

D. Neuberg, Catherine J. Wu, S. Rodig, 2020 .

Prognosis of patients with intermediate risk IPSS‐R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS‐R

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2018, American journal of hematology.

C‐terminal nucleophosmin mutations are uncommon in chronic myeloid disorders

D. Steensma, A. Tefferi, T. Lasho, 2006, British journal of haematology.

Vladimir Prelog—Nobel Prize for Work in Stereochemistry

R. Kyle, D. Steensma, M. Shampo, 2008 .

Clarifications to the standard neutrophil response criteria for clinical trials in myelodysplastic syndromes are needed.

D. Steensma, A. Tefferi, L. Letendre, 2001, Blood.

Processes to activate phase III clinical trials in a cooperative oncology group: the elephant is monstrous.

D. Steensma, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Myelodysplastic syndromes current treatment algorithm 2018

D. Steensma, 2018, Blood Cancer Journal.

Use of CME to impact self-reported changes in the evaluation and management of anaemia in geriatric patients

D. Steensma, P. Walden, B. Dennison, 2015 .

Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia

D. Steensma, R. Mesa, D. Loegering, 2011, Haematologica.

Anemia or low hemoglobin levels preceding Parkinson disease

D. Maraganore, W. Rocca, B. Grossardt, 2009, Neurology.

Crystal-storing histiocytosis: An unusual relapsing inflammatory CNS disorder.

J. Parisi, C. Lucchinetti, D. Bourdette, 2012, Multiple sclerosis and related disorders.

The relationship between serum hepcidin levels and clinical outcomes in patients with chemotherapy-associated anemia treated in a controlled trial.

C. Loprinzi, D. Steensma, B. Sasu, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recombinant Human Erythropoiesis Stimulating Agents in Cancer Patients: Individual Patient Data Meta-Analysis on Behalf of the EPO IPD Meta-Analysis Collaborative Group

M. Zwahlen, M. Egger, M. Schumacher, 2008 .

Caring for the whole patient: the science of psychosocial care.

J. Holland, P. Jacobsen, D. Steensma, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Should oncologists support the Affordable Care Act?

H. Kantarjian, D. Steensma, D. Light, 2013, The Lancet. Oncology.

The origin and evolution of the term "clone".

D. Steensma, 2017, Leukemia research.

Spatial wavefunction for photoionization from a one-dimensional delta-function potential

D. Steensma, S. Haan, R. Steen, 1994 .

Patient-Reported Outcomes Associated with Different Treatments for Myelodysplastic Syndromes

G. Abel, D. DeAngelo, D. Steensma, 2016 .

Feasibility of Routine Frailty Screening Assessment for Patients in a Hematologic Oncology Clinic: Results from a Pilot Study

Nolan B. Condron, G. Abel, J. Laubach, 2015 .

Transplant Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care.

D. Revicki, G. Garcia-Manero, J. Maciejewski, 2023, Transplantation and cellular therapy.

Alois Alzheimer--Alzheimer disease.

R. Kyle, D. Steensma, M. Shampo, 2013, Mayo Clinic proceedings.

An MLL-SEPT9 fusion and t(11;17)(q23;q25) associated with de novo myelodysplastic syndrome.

D. Steensma, R. Ketterling, J. C. Porcher, 2007, Leukemia research.

A premature obituary for erythropoietin analogues.

D. Steensma, 2008, The Lancet. Oncology.

A novel splicing mutation in the gene encoding the chromatin-associated factor ATRX associated with acquired hemoglobin H disease in myelodysplastic syndrome (ATMDS)

D. Higgs, D. Steensma, C. Fisher, 2004 .

Corrigendum to “The myelodysplastic syndrom(s): a perspective and review highlighting current controversies” [Leuk. Res. 27 (2004) 95–120]

D. Steensma, A. Tefferi, 2005 .

Promising Results of a Phase 1/2 Clinical Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia

D. Steensma, R. Mesa, J. Lancet, 2017 .

H3B-8800-G0001-101: A first in human phase I study of a splicing modulator in patients with advanced myeloid malignancies.

M. Warmuth, P. Greenberg, M. Maris, 2017 .

Tadeus Reichstein-work on hormones of the adrenal glands.

R. Kyle, D. Steensma, M. Shampo, 2013, Mayo Clinic proceedings.

Health care utilization and end‐of‐life care for older patients with acute myeloid leukemia

J. Temel, T. Graubert, K. Ballen, 2015, Cancer.

Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

H. Deeg, F. Thol, P. Greenberg, 2019, Blood.

A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation On the Erythropoietic Response to Darbepoetin Alfa for Patients with Chemotherapy-Associated Anemia: A Study of the Mayo Clinic Cancer Research Consortium (MCCRC).

P. Novotny, J. Sloan, C. Loprinzi, 2009 .

Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

E. Vellenga, D. Steensma, P. Fenaux, 2019, Blood.

Does early diagnosis and treatment of myelodysplastic syndromes make a difference?

D. Steensma, 2019, Best practice & research. Clinical haematology.

An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS

R. Bejar, O. Abdel-Wahab, P. Greenberg, 2022, Blood advances.

Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Demonstrate DHRS3 Induction and Myeloid Differentiation Following Sy-1425 Treatment

M. McKeown, J. Cortes, D. Steensma, 2017 .

Detection of Recurrent Mutations by Pooled Targeted Next-Generation Sequencing in MDS Patients Prior to Treatment with Hypomethylating Agents or Stem Cell Transplantation

K. Cibulskis, D. Neuberg, B. Ebert, 2012 .

The ordinary miracle of cancer clinical trials.

D. Steensma, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Stamp vignette on medical science. Vincent du Vigneaud-Nobel Prize in chemistry.

R. Kyle, D. Steensma, M. Shampo, 2013, Mayo Clinic proceedings.

Enough already of the word "robust"!

D. Steensma, 2004, Blood.

Edward L. Trudeau--founder of a sanatorium for treatment of tuberculosis.

R. Kyle, D. Steensma, M. Shampo, 2010, Mayo Clinic proceedings.

Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).

Tae Kon Kim, R. Bejar, O. Abdel-Wahab, 2023, Blood reviews.

Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: Clinicopathologic correlations and new insights from the prelenalidomide era

D. Steensma, A. Tefferi, G. Dewald, 2008, American journal of hematology.

Myelodysplastic Syndrome

D. Steensma, N. Vey, V. Gelsi-Boyer, 2020, Definitions.

Abstract 2954: Immunomodulator maintenance post autologous stem cell transplant predicts better outcome in multiple myeloma patients with clonal hematopoiesis of indeterminate potential

D. Neuberg, B. Ebert, N. Munshi, 2018, Clinical research.

Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemia

L. Trippa, D. Steensma, S. Treon, 2021, Blood advances.

Elevated serum LDH in patients with non‐Hodgkin's lymphoma: not always an ominous sign

D. Steensma, T. Witzig, 1999, British journal of haematology.

Importance of Complete Remission on Predicting Overall Survival in Patients with Lower-Risk Myelodysplastic Syndromes (MDS)

J. Barnard, G. Garcia-Manero, J. Maciejewski, 2016 .

Severe coagulation factor V deficiency associated with an interstitial deletion of chromosome 1q

R. Sood, D. Steensma, R. Pruthi, 2007, Journal of thrombosis and haemostasis : JTH.

Oscar (Oskar) Minkowski: discovery of the pancreatic origin of diabetes.

R. Kyle, D. Steensma, M. Shampo, 2015, Mayo Clinic proceedings.

Speaking a common language in MDS/MPNs.

D. Steensma, 2015, Blood.

John Shaw Billings: Civil War Surgeon, Medical Librarian, Founder of Index Medicus, and First Director of the New York Public Library.

R. Kyle, D. Steensma, 2019, Mayo Clinic proceedings.

ALG/ATG: illuminating the occult

D. Steensma, 2003 .

Acquired somatic ATRX mutations in myelodysplastic syndrome associated with alpha thalassemia (ATMDS) convey a more severe hematologic phenotype than germline ATRX mutations.

D. Higgs, D. Steensma, C. Fisher, 2004, Blood.

Transplant Referral Patterns for Patients (Pts) with Newly Diagnosed (ND) Higher-Risk (HR) Myelodysplastic Syndromes (MDS), and European Leukemianet (ELN) 2010 Intermediate-Risk (IR) or Adverse-Risk (AR) Acute Myeloid Leukemia (AML) in the Connect® MDS/AML Registry

D. Steensma, M. Sekeres, D. Pollyea, 2020 .

Overall survival (OS) and baseline disease characteristics in MDS patients with primary HMA failure in a randomized, controlled, phase III study of rigosertib.

R. Collins, P. Greenberg, G. Gaidano, 2015 .

Prognostic and predictive value of IPSS-R in assessing overall survival (OS) in a phase III study of rigosertib in second-line higher-risk (HR) MDS patients.

R. Collins, P. Greenberg, G. Gaidano, 2015 .

Does treatment with recombinant human erythropoietin affect the survival of anemic patients with cancer?

D. Steensma, T. Witzig, 2005, Nature Clinical Practice Oncology.

Oddballs: acute leukemias of mixed phenotype and ambiguous origin.

D. Steensma, 2011, Hematology/oncology clinics of North America.

Absence of frataxin mutations in refractory anemia with ring sideroblasts (RARS).

D. Steensma, J. C. Porcher, N. Gangat, 2009, Leukemia research.

The kiss of death: a severe allergic reaction to a shellfish induced by a good-night kiss.

D. Steensma, 2003, Mayo Clinic proceedings.

Health care utilization and end‐of‐life care for older patients with acute myeloid leukemia

J. Temel, T. Graubert, K. Ballen, 2015, Cancer.

Rethinking clinical trial endpoints in myelodysplastic syndromes

D. Steensma, M. Sekeres, 2019, Leukemia.

The JAK2 V617F Tyrosine Kinase Mutation in Myelofibrosis with Myeloid Metaplasia: Clinical Correlates and Prognostic Relevance in 157 Patients.

D. Gilliland, D. Steensma, M. Wadleigh, 2005 .

Myelodysplastic Syndromes

D. Steensma, Richard M Stone, 2020, Abeloff's Clinical Oncology.

POLYRADICULOPATHY DUE TO METHOTREXATE-INDUCED EBV-ASSOCIATED LYMPHOPROLIFERATIVE DISORDER

D. Steensma, H. Luthra, P. Sandroni, 2008, Neurology.

Novel therapies for myelodysplastic syndromes.

D. Steensma, 2010, Hematology/oncology clinics of North America.

P39/Tsugane cells are a false cell line contaminated with HL-60 cells and are not suitable for mechanistic studies in myelodysplastic syndromes

D. Steensma, 2010, Haematologica.

Clinical Outcomes and Evolution of Clonal Hematopoiesis in Patients with Newly Diagnosed Multiple Myeloma

Andrew J. Dunford, C. Stewart, J. Keats, 2023, Cancer research communications.

How I use molecular genetic tests to evaluate patients who have or may have myelodysplastic syndromes.

D. Steensma, 2018, Blood.

Acquired somatic ATRX mutations in myelodysplastic syndrome associated with alpha thalassemia (ATMDS) convey a more severe hematologic phenotype than germline ATRX mutations.

D. Higgs, D. Steensma, C. Fisher, 2004, Blood.

Key Opinion Leaders.

D. Steensma, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The mosaic of Myeloid Neoplasia: Implications for Classification

D. Steensma, 2008, Leukemia & lymphoma.

MYELOID NEOPLASIA Acute myeloid leukemia ontogeny is de ﬁ ned by distinct somatic mutations

D. DeAngelo, D. Steensma, M. Wadleigh, 2015 .

MYELOID NEOPLASIA Acute myeloid leukemia ontogeny is de ﬁ ned by distinct somatic mutations

D. DeAngelo, D. Steensma, M. Wadleigh, 2015 .

MYELOID NEOPLASIA Acute myeloid leukemia ontogeny is de ﬁ ned by distinct somatic mutations

D. DeAngelo, D. Steensma, M. Wadleigh, 2015 .

Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes

G. Garcia-Manero, D. Steensma, U. Borate, 2023, American journal of hematology.

Reply to J.S. Abrams et al.

H. Kantarjian, D. Steensma, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Terry Fox: Canadian cancer research activist whose "Marathon of Hope" inspired millions.

R. Kyle, D. Steensma, D. Rayson, 2014, Mayo Clinic proceedings.